Accelerate Diagnostics
AXDX
AXDX was delisted on the 14th of May, 2025.
109 hedge funds and large institutions have $513M invested in Accelerate Diagnostics in 2019 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 30 increasing their positions, 28 reducing their positions, and 18 closing their positions.
7% more repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 28
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
4% less funds holding
Funds holding: 113 → 109 (-4)
7% less capital invested
Capital invested by funds: $551M → $513M (-$38.9M)
22% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 18
53% less call options, than puts
Call options by funds: $5.37M | Put options by funds: $11.4M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$12.4M |
| 2 |
CC
Chicago Capital
Chicago,
Illinois
|
+$7.14M |
| 3 |
Axa
Paris,
France
|
+$4.13M |
| 4 |
GAM
Griffin Asset Management
New York
|
+$2.97M |
| 5 |
AG
Artal Group
Luxembourg
|
+$1.65M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
William Blair & Company
Chicago,
Illinois
|
-$4.27M |
| 2 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$4.27M |
| 3 |
NCGI
Next Century Growth Investors
Plymouth,
Minnesota
|
-$3.35M |
| 4 |
First Trust Advisors
Wheaton,
Illinois
|
-$2.43M |
| 5 |
OIM
Oracle Investment Management
Greenwich,
Connecticut
|
-$2.23M |
AXDX Hedge Fund Activity: Q4 2019 in Review
109 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Accelerate Diagnostics (AXDX) for Q4 2019, worth a combined $513M — down 7.1% from $551M a quarter earlier.
Sellers outnumbered buyers: 18 funds closed out of AXDX and 14 opened new positions — a net loss of 4 holders — while 28 trimmed existing stakes and 30 added.
The largest buyer was Fidelity Investments, adding an estimated $12.4M. The largest seller was William Blair & Company, cutting an estimated $4.27M.
- 109 institutional investors held Accelerate Diagnostics (AXDX) as of Q4 2019, down from 113 in Q3 2019.
- Funds reported $513M of Accelerate Diagnostics stock for Q4 2019, down 7.1% quarter-over-quarter.
- 14 funds opened new Accelerate Diagnostics positions in Q4 2019 and 18 closed out, a net change of -4 holders.
- The largest Accelerate Diagnostics buyer in Q4 2019 was Fidelity Investments, an estimated $12.4M added.
- The largest Accelerate Diagnostics seller in Q4 2019 was William Blair & Company, an estimated $4.27M sold.
Based on aggregated 13F filings for Q4 2019.